Drug makers say IP barriers not the bottleneck in boosting vaccine production By Reuters
ZURICH (Reuters) - Manufacturing capacity and shortages of ingredients are the main bottlenecks in expanding COVID-19 vaccine production, a drug industry group said on Tuesday, not the patents that some groups want removed. "IP (intellectual property) rights is not the issue. The bottlenecks are the capacity, the scarcity of raw materials, scarcity of ingredients, and it is about the know-how," Thomas...
Continue reading